IBDEI0KR ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10172,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,10172,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,10173,0)
 ;;=238.4^^67^672^109
 ;;^UTILITY(U,$J,358.3,10173,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10173,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,10173,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,10173,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,10174,0)
 ;;=V58.61^^67^672^126
 ;;^UTILITY(U,$J,358.3,10174,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10174,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,10174,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,10174,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,10175,0)
 ;;=282.49^^67^672^117
 ;;^UTILITY(U,$J,358.3,10175,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10175,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,10175,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,10175,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,10176,0)
 ;;=289.89^^67^672^15
 ;;^UTILITY(U,$J,358.3,10176,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10176,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,10176,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,10176,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,10177,0)
 ;;=238.79^^67^672^88
 ;;^UTILITY(U,$J,358.3,10177,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10177,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,10177,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,10177,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,10178,0)
 ;;=287.30^^67^672^110
 ;;^UTILITY(U,$J,358.3,10178,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10178,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,10178,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,10178,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,10179,0)
 ;;=288.09^^67^672^8
 ;;^UTILITY(U,$J,358.3,10179,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10179,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,10179,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,10179,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,10180,0)
 ;;=V10.21^^67^672^61
 ;;^UTILITY(U,$J,358.3,10180,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10180,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,10180,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,10180,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,10181,0)
 ;;=284.2^^67^672^106
 ;;^UTILITY(U,$J,358.3,10181,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10181,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,10181,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,10181,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,10182,0)
 ;;=202.40^^67^672^76
 ;;^UTILITY(U,$J,358.3,10182,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10182,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,10182,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,10182,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,10183,0)
 ;;=287.49^^67^672^118
 ;;^UTILITY(U,$J,358.3,10183,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10183,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,10183,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,10183,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,10184,0)
 ;;=180.9^^67^672^29
 ;;^UTILITY(U,$J,358.3,10184,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10184,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,10184,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,10184,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,10185,0)
 ;;=203.02^^67^672^104
 ;;^UTILITY(U,$J,358.3,10185,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,10185,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,10185,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,10185,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,10186,0)
 ;;=204.02^^67^672^2
